Tous Actualités
Suivre
Abonner Intercell AG

Intercell AG

euro adhoc: Intercell AG
Mergers - Acquisitions - Takeovers
Intercell announces intention to acquire Pelias AG to strengthen its product portfolio and strategic focus in hospital-acquired infections

  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.
06.12.2006
» Vienna-based Pelias AG focuses on the development of novel vaccines
against    hospital-acquired infections - the company’s lead product,
a novel protein    based vaccine against Pseudomonas infections, is
in clinical trials » Full integration of vaccine projects in the
field of hospital-acquired    infections will strengthen Intercell’s
product portfolio and strategic focus    in a market with high unmet
medical need » As consideration for the acquired shares, up to
350,000 new Intercell shares    from existing authorized capital will
be offered to selling Pelias    shareholders
Intercell AG today announced its intention to increase its
shareholding in the Vienna-based Pelias Biomedical Development AG
("Pelias") from currently 46 percent to a shareholding of 100
percent. In an all-share deal, Intercell offers up to 350,000 new
Intercell shares, representing about 0.9 percent of Intercell’s
current share capital, to the remaining private shareholders of
Pelias. The transaction, which is subject to certain closing
conditions required by Austrian law, is expected to close early 2007.
Pelias develops products and holds certain licenses in the field of
vaccines against important pathogens involved in hospital-acquired
infections, including a clinical stage Pseudomonas vaccine candidate
and a number of antigens, which have been identified by Intercell’s
proprietary Antigen Identification Program (AIP®). Hospital-acquired
infections are one of the major causes of death and serious illness
worldwide and result in an annual burden of USD 20 billion in the
developed world.
"The attractive product portfolio combined with our enabling
technologies offer us a unique opportunity to expand our globally
leading position as technology provider and vaccine developer in the
field of hospital-acquired infections", states Intercell's CEO Gerd
Zettlmeissl.
"Our clinical progress with our Japanese Encephalitis vaccine and our
strong financial position allow us to broaden our pipeline in an
attractive field with high unmet medical need. Our enlarged product
portfolio will support our position in leading vaccine innovation
without any major implications on our business plan", states Werner
Lanthaler, CFO of Intercell.
About hospital-acquired infections
Nosocomial infections - or hospital acquired infections - are
bacterial or fungal infections which are acquired in a hospital
setting and cause a variety of severe infections, many
life-threatening such as pneumonia, sepsis and bacteremia.  Each
year, around 2 million infections and 100,000 deaths occur in the US
alone due to nosocomial infections. The annual burden to the society
is constantly increasing due to the antibiotics resistance of the
most problematic bacteria. In the field of S. aureus infections
Intercell has a strong strategic alliance with Merck & Co., Inc. with
a vaccine product in clinical trials.
Market Potential
Hospital-acquired infections represent a large market with an urgent,
unmet medical need:
» Nosocomial infections are one of the major causes of death and
serious    illness worldwide. » Conservative estimates put the number
of hospital-acquired infections at    around 2 million per year only
in the US, leading to around 100,000 deaths    and resulting into an
accumulated annual burden of more than USD 20 billion    in the
developed world. » These numbers are expected to more than double by
2010. The combined market    volume in the US and EU is currently
estimated at around USD 5 billion.
end of announcement                               euro adhoc 06.12.2006 07:03:02

Further inquiry note:

Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market

Plus de actualités: Intercell AG
Plus de actualités: Intercell AG